Welcome to the Hope Bio Blog

By Jan Shultis, Ph.D. As 2026 progresses, so, too, does research exploring Hope Biosciences’ proprietary cellular therapeutics in brain injury. Calendar year 2026 commenced with our cells at work in a Phase II clinical trial in Traumatic Brain Injury (TBI) executed by UTHealth Houston; early summer brought peer-reviewed publication in globe-leading neurology journal Brain of results of another TBI trial using our cells; and as summer presses on, we are delighted to begin manu

Notes, sources, and more for Stem Cell Revolution's recent deep dive into sports, concussions, and CTE By the Hope Biosciences Editorial Team Hopefully you've already enjoyed the most recent episode of Stem Cell Revolution (SCR), available on YouTube and Spotify. (If you haven't seen it yet, it's available above. Click here for more episodes on an array of topics, and please check back each month when new conversations drop!). This month, Houston is proud to host the World Cu

By Jan Shultis, Ph.D. Last year, Hope Biosciences was privileged to announce a four-year, nearly $5 million clinical trial grant awarded by the Department of Defense’s Office of Congressionally Directed Medical Research Programs (CDMRP) to evaluate if intravenously infused Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce chronic neuroinflammatory response to severe traumatic brain injury (TBI). Hope Biosciences with the team at UTHealt